Saturday 17 October 2026
Export PROK’s income statement to Excel — free account
ProKidney Corp.
PROK Healthcare Biotechnology
ProKidney Corp.’s revenue for fiscal 2025 (year ended December 2025) was $893,000.00, up 1,075.0% from fiscal 2024. In the quarter to June 2026, revenue fell 32.1%, EPS fell 15.4% and free cash flow fell 28.0%, each against the same quarter a year earlier.
1.33
0.13
−8.90%
Follow PROK
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '17 | |
|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | — | — | — | — |
Altman Z-Score |
(5.89) | (4.14) | — | — | — | — | — |
P/S ratio |
335.98 | 0.00 | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(11.54) | (7.05) | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | — | — | — | — | — |
Beneish M-Score |
6.16 | — | — | — | — | — | — |
P/Operating CF |
(9.23) | (6.85) | — | — | — | — | — |
P/B ratio |
0.00 | 0.00 | — | — | — | — | — |
Price to Tangible BV |
0.00 | 0.00 | — | — | — | — | — |
EV/Sales |
33.98 | 0.00 | — | — | — | — | — |
EV/EBITDA |
0.00 | 1.08 | — | — | — | — | — |
EV/Operating CF |
(0.25) | 1.52 | — | — | — | — | — |
EV/FCF |
(0.26) | 1.24 | — | — | — | — | — |
Quick Ratio |
8.82 | 9.96 | 14.55 | 45.09 | 1.67 | — | — |
Current Ratio |
9.13 | 10.93 | 14.94 | 46.42 | 2.21 | — | — |
Net Debt/EBITDA |
1.70 | 2.01 | 2.46 | 3.27 | 0.39 | 0.00 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
1.74 | 2.07 | 2.54 | 0.71 | 0.91 | 0.94 | — |
Capex/Depreciation |
0.46 | (5.43) | (8.88) | (0.61) | (2.62) | (5.66) | — |
Interest Coverage |
(41,251.75) | (20,408.44) | (12,626.83) | (711.66) | (27,555.00) | — | — |
| 6.88% | 5.83% | 3.22% | 20.20% | 0.00% | 0.00% | — | |
| (17.77%) | (14.20%) | (7.56%) | (38.70%) | (273.69%) | 0.00% | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (541.65%) | 0.00% | — |
Return on Tangible Assets |
(22.91%) | (15.22%) | (9.07%) | (21.41%) | (209.56%) | 0.00% | — |
Average Days of Receivables |
460.64 | 11,752.04 | 0.00 | — | — | — | — |
Research and Development Expense of Revenue |
12,779.73% | 167,984.21% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
5,798.10% | 73,794.74% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
2,837.18% | 38,647.37% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Graham Net Nets |
(3.55) | (6.29) | — | — | — | — | — |
Graham Number |
9.40 | 12.00 | — | — | — | — | — |
Earnings Yield |
(23.21%) | (37.28%) | — | — | — | — | — |
Free Cash Flow Yield |
(39.03%) | (94.19%) | — | — | — | — | — |
Revenue per Share |
0.01 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Operating CF per Share |
(0.90) | (1.29) | (1.46) | (1.25) | (0.82) | 0.00 | — |
Capex per Share |
0.02 | (0.30) | (0.55) | (0.03) | (0.08) | 0.00 | — |
Free Cash Flow per Share |
(0.87) | (1.59) | (2.01) | (1.28) | (0.90) | 0.00 | — |
Cash per Share |
2.02 | 3.66 | 5.88 | 7.97 | 0.33 | — | — |
Shareholders Equity per Share |
(7.55) | (10.16) | (17.88) | (17.82) | 0.44 | 0.00 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Book value per Share |
(7.55) | (10.16) | (17.88) | (17.82) | 0.44 | 0.00 | — |
Free Cash Flow |
(117.10) | (155.86) | (124.27) | (78.93) | (55.49) | (30.64) | — |
Working Capital |
249.94 | 359.67 | 349.11 | 493.85 | 14.96 | — | — |
Capital Expenditures |
3.02 | (29.51) | (34.20) | (1.85) | (5.19) | (5.46) | — |
Net Current Asset Value |
(1,066.09) | (1,040.14) | (1,149.80) | (1,109.89) | 13.89 | 0.00 | — |
EV/EBIT |
0.00 | 1.05 | — | — | — | — | — |
Capex to Sales |
(3.38) | 388.28 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Price to Operating Income |
0.00 | 0.00 | — | — | — | — | — |
| Other line items | |||||||
Depreciation/Fixed assets |
0.13 | 0.13 | 0.09 | 0.28 | 0.17 | 0.00 | — |
Cash ROIC |
15.80% | 24.48% | 16.78% | 13.02% | (116.88%) | 0.00% | — |
Accounts Receivable Turnover |
0.50 | 0.04 | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — |
Average Receivables |
1.79 | 1.91 | — | — | — | — | — |
Average Payables |
2.29 | 4.37 | 4.07 | 2.94 | — | — | — |
Average Assets |
388.32 | 430.81 | 469.27 | 279.15 | 20.15 | 0.00 | — |
Average Common Equity |
(1,003.08) | (1,049.17) | (1,100.01) | (534.85) | — | — | — |
Columns are period end dates